<DOC>
	<DOCNO>NCT00272584</DOCNO>
	<brief_summary>This 9 week , multicentre , randomize , double-blind , placebo-controlled trial two parallel group . There also open-label extension phase 18 week . Both medication use study , clozapine risperidone , fully approve treatment schizophrenia .</brief_summary>
	<brief_title>CARE Study : Improving Treatment Most Severely Ill With Schizophrenia</brief_title>
	<detailed_description>Subjects may inpatients outpatient . All subject treat throughout study clozapine , dose 400 mg , unless limited side effect . After screen , subject augment placebo 7 day . Any subject reduction PANSS total score 20 % great discontinue study . Beginning day 8 , subject randomize continued augmentation clozapine placebo , augmentation risperidone . The initial daily dose risperidone 1.0 mg , increase 1.0 mg increment total 3.0 mg/day two week period . Subjects unable tolerate least one tablet study medication drop study . At end 8 week follow randomization , choice investigator , open-label risperidone augmentation start . The primary outcome measure PANSS total score week 9 . Subjects classify responder improvement PANSS total score 20 % great , proportion responder group determine . Complementary outcome measure CGI severity score , CGI improvement score , SOFAS score . Safety tolerance assess report adverse event clinically significant change vital sign , weight , waist circumference , extrapyramidal side effect , metabolic hematological measure .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Subjects treat clozapine indication poor response antipsychotic medication . Treatment clozapine stable dose least 12 week . Dose must 400 mg/day , unless side effect limited increase dose . Subjects significant alcohol substance abuse past 3 month . Subjects previous trial risperidone augmentation clozapine Subjects pregnant , breastfeeding , woman childbearing potential use adequate contraception Subjects require treatment anticonvulsant . Subjects know hypersensitivity allergy risperidone . Subjects hematological contraindication continue clozapine treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Psychosis , schizophrenia , schizoaffective , clozapine , risperidone</keyword>
</DOC>